Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the publication

BusinesswireApr 16 04:05

Cantor Fitzgerald Corp.: Prothena Corp (PRTA.US) shareholding rating confirmed.

Cantor Fitzgerald Corp.: Prothena Corp (PRTA.US) shareholding rating confirmed.

Zhitong FinanceApr 11 01:31

Cantor Fitzgerald Reiterates Overweight on Prothena Corp

Cantor Fitzgerald analyst Charles Duncan reiterates Prothena Corp with a Overweight.

Analyst UpgradesApr 11 01:26

Despite Shrinking by US$81m in the Past Week, Prothena (NASDAQ:PRTA) Shareholders Are Still up 108% Over 5 Years

Some Prothena Corporation plc (NASDAQ:PRTA) shareholders are probably rather concerned to see the share price fall 43% over the last three months. But that doesn't change the fact that the returns

Simply Wall StApr 5 19:25

Labcorp Expands Alzheimer's Testing Portfolio With New Diagnostic

Seeking AlphaMar 20 21:00

Prothena Is Maintained at Buy by HC Wainwright & Co.

Prothena Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 13 21:36